Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult Subjects

Moderna

Status and phase

Completed

Phase 1

Conditions

Influenza

Treatments

Biological: VAL-506440

Other: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT03076385

2015-003452-48 (EudraCT Number)

VAL-506440-P101

Details and patient eligibility

About

This clinical study will assess the safety, tolerability and immunogenicity of VAL-506440 in healthy adult subjects.

Enrollment

201 patients

Sex

All

Ages

18 to 64 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion

Agrees to comply with the study procedures and provides written informed consent
18 to 64 years of age
Body mass index between 18 and 30 kg/m2
Negative urine pregnancy test at the Screening visit and the day of each vaccination.
Female subjects must either be of non-childbearing potential or use highly effective methods of contraception from at least 2 months before the Screening Visit through 3 weeks post last vaccination
In good health based on medical history, physical examination, vital sign measurements and laboratory safety tests performed prior to initial study vaccination

Exclusion

Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care
Administration of an investigational product within 45 days
Women who are pregnant or breastfeeding, or plan to become pregnant during the study
Prior administration of investigational agent using formulations similar to VAL-506440
History of a serious reaction to prior influenza vaccinations
History of Guillain-Barré Syndrome within 6 weeks following a previous influenza vaccine
Administration of any live attenuated vaccines within 4 weeks before enrollment, inactive vaccines within 2 weeks before enrollment, or plans to any vaccine within the vaccination period
Any known or suspected immunosuppressive condition, acquired or congenital, as determined by history and/or physical examination
Any chronic administration of immunosuppressant or other immune-modifying drugs within 6 months prior to administration of study vaccine
Administration of immunoglobulins and/or any blood products within the 3 months preceding the administration of the study vaccine or during the study.
Any acute disease at the time of enrollment
Any bleeding risk or thromboembolic event or any related medical history
Regular alcohol consumption > 3 units/day, or current user of any illicit drugs, or has a history of drug/alcohol abuse with 1 year of screening or has a positive urine drug/alcohol test at screening
Persons employed in a capacity that involves handling poultry or wild birds
Unable to refrain from or anticipates the use of any medication, including prescription and non-prescription drugs or herbal remedies within 4 weeks before administration of the first vaccination, throughout the study
Had major surgery or donation of blood or blood products within 4 weeks of dosing
Current smoking of more than 10 cigarettes (or equivalent amount of tobacco) per day, and within 3 months prior to Screening
Subject is an employee of the Sponsor or CRO involved in the study.
Vulnerable subjects (e.g., a subject kept in detention).
Any condition, that in the opinion of the Investigator would pose a health risk to the subject if enrolled or could interfere with evaluation of the vaccine or interpretation of the study results
History of autoimmune disease
Inadequate Liver Function as defined by AST, ALT, GGT, alkaline phosphatase and bilirubin > 1.5xULN
Known allergy or history of anaphylaxis or other serious adverse reactions to any of the constituents of the study vaccine